Welcome to LookChem.com Sign In|Join Free
  • or
N2'-deacetyl-N2'-(4-methyl-4-methythio-1-oxopentyl)maytansine, also known as M197940, is an active metabolite of Maytansine. It is a complex organic compound with a unique structure that allows it to inhibit the in vitro polymerization of tubulin, a key component of microtubules in cells. This property makes it a promising candidate for the development of anticancer drugs.

890654-03-2

Post Buying Request

890654-03-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

890654-03-2 Usage

Uses

Used in Oncology:
N2'-deacetyl-N2'-(4-methyl-4-methythio-1-oxopentyl)maytansine is used as an anticancer agent for the treatment of advanced breast cancer. Its ability to inhibit tubulin polymerization disrupts the normal function of microtubules, which are essential for cell division and maintenance of cell shape. This leads to the inhibition of cancer cell proliferation and the induction of cell death, making it a valuable tool in the fight against breast cancer.

Check Digit Verification of cas no

The CAS Registry Mumber 890654-03-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,9,0,6,5 and 4 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 890654-03:
(8*8)+(7*9)+(6*0)+(5*6)+(4*5)+(3*4)+(2*0)+(1*3)=192
192 % 10 = 2
So 890654-03-2 is a valid CAS Registry Number.

890654-03-2Downstream Products

890654-03-2Relevant academic research and scientific papers

Metabolites of antibody-maytansinoid conjugates: Characteristics and in vitro potencies

Widdison, Wayne,Wilhelm, Sharon,Veale, Karen,Costoplus, Juliet,Jones, Gregory,Audette, Charlene,Leece, Barbara,Bartle, Laura,Kovtun, Yelena,Chari, Ravi

, p. 1762 - 1773 (2015/06/16)

Several antibody-maytansinoid conjugates (AMCs) are in clinical trials for the treatment of various cancers. Each of these conjugates can be metabolized by tumor cells to give cytotoxic maytansinoid metabolites that can kill targeted cells. In preclinical

Elimination of heterogeneous or mixed cell population in tumors

-

Page/Page column 21; Sheet 20/20, (2008/06/13)

Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates have therapeutic use as they are delivered to a specific cell population to kill these cells and the cytotoxic drug is released to kill non-targeted cells, thereby eliminating the tumor.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 890654-03-2